A Novel Combination Oral Agent to Treat Acne Vulgaris

Status unconfirmed · Phase 1/Phase 2

Conditions studied: ACNE VULGARIS

In brief

The purpose of this study is to evaluate a novel, combination product for the treatment of acne vulgaris in females

Key facts

Study ID

NCT01301586

Run by

Nexgen Dermatologics, Inc.

People needed

60

Starts

2010-11-01

Expected to finish

2011-09-01

Last updated by the study team

2011-02-23

Who can join

Age: 13 and older, up to 60. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Healthy females 13 years of age or older
• Non-pregnant, non-lactating females
• Signed written informed consent form
• Must be able to understand and be willing to follow all study instructions
• Have a clinical diagnosis of acne vulgaris

You may not qualify if…

• Female subjects who are pregnant or nursing
• Any concomitant dermatologic condition that may affect outcome measures
• Concurrent use of any other medication to treat acne vulgaris
• Have a history or clinical evidence of any other active acute or chronic medical disease or condition considered by the principal investigator as unsuitable for the study
• Are currently using any other investigational agent or device
• Have participated in any other clinical study within 90 days prior to enrollment
• Employees or family members of sponsor or research site

Where it is running

• Palos Verdes Dermatology Associates — Rolling Hills Estates, California, United States (enrolling)
• Berlin Center — Boynton Beach, Florida, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.